Edwards Lifesciences Sees FY24 Adj. EPS $2.70-$2.80 Vs $2.76 Est.; Revenue $6.3B-$6.6B Vs $6.516B Est.
Portfolio Pulse from Benzinga Newsdesk
Edwards Lifesciences projects its FY24 adjusted EPS to be between $2.70 and $2.80, compared to the estimated $2.76, and anticipates revenues to range from $6.3 billion to $6.6 billion, versus the estimated $6.516 billion.
April 25, 2024 | 8:20 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Edwards Lifesciences anticipates FY24 adjusted EPS to be in the range of $2.70-$2.80, closely matching the consensus estimate of $2.76, with revenue projections of $6.3B-$6.6B, slightly varying from the estimated $6.516B.
The guidance provided by Edwards Lifesciences for FY24 is closely aligned with analyst estimates, indicating a neutral impact on the stock price. The slight variance in revenue projections suggests cautious optimism but is unlikely to significantly move the stock in the short term due to the alignment with expectations.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100